Kathline Kim Email Address

Clinical Science-Narrative Quality Control Reviewer

Founded in 2008, NGM is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases. The Company is focused on discovering the next generation of therapeutics that will fundamentally change the treatment paradigm for the growing population of cardiometabolic disease patients worldwide, and NGM's core assets enable us to deliver on that promise: High-throughput platform that can discover protein and peptide hormones, as well as other druggable targets with interesting physiological activity in the gastrointestinal (GI) tract and other metabolically-relevant tissues Integrated translational research and protein sciences capabilities to enable a program to seamlessly advance from discovery to clinical development Accomplished research and management team with deep drug discovery and protein sciences experience World-class advisors with expertise in metabolic diseases, bariatric surgery science and biologics drug discovery and development NGM has identified a rich pipeline of novel targets with profound metabolic effects in various animal models of diabetes, obesity and muscle wasting.

Clinical Trial Manager at NGM Biopharmaceuticals